IP Library Granted Patent US 7,901,682
Granted Patent B2
US 7,901,682 · App. 11/638,730 · Granted Mar 8, 2011

Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,901,682
App. No.
11/638,730
Granted
Mar 8, 2011
Kind
B2
Abstract

Methods and compositions are disclosed that are useful for the prevention and/or treatment of cancer, angiogenesis, and inflammation. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that bind sphingolipids or sphingolipid metabolites. In one embodiment the agent is an antibody or antibody derivative. In some embodiments, the agent is a receptor of a sphingolipid or a sphingolipid metabolite. Also disclosed are methods for identifying and isolating therapeutic agents.

Claims (7)

1. A method for treating a disease or disorder correlated with a sphingolipid or a sphingolipid metabolite, comprising administering to a patient an amount of an antibody or antibody fragment that binds sphingosine-1-phosphate effective to reduce the effective concentration of the sphingosine-1-phosphate, wherein the disease or disorder is selected from the group consisting of cancer, pathologic angiogenesis, and pathologic inflammation.

2. A method according to claim 1 wherein the disease or disorder is cancer.

3. A method according to claim 1 wherein the antibody is a monoclonal antibody.

4. A method according to claim 1 wherein the antibody is a humanized monoclonal antibody.

5. A method according to claim 1 wherein the antibody fragment is an antibody fragment that comprises at least one antigen-binding domain specific for sphingosine-1-phosphate.

6. A method according to claim 1 wherein the disease or disorder is pathologic angiogenesis.

7. A method according to claim 1 wherein the disease or disorder is pathologic inflammation.

Assignments (6)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 5, 2023
From: APOLLO ENDOSURGERY, INC.; APOLLO ENDOSURGERY US, INC.; APOLLO ENDOSURGERY INTERNATIONAL, LLC; LPATH THERAPEUTICS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 063264/0046 →
RELEASE OF SECURITY INTEREST Recorded Dec 30, 2021
From: SLR INVESTMENT CORP. (F/K/A SOLAR CAPITAL LTD.)
To: APOLLO ENDOSURGERY US, INC.; APOLLO ENDOSURGERY INTERNATIONAL, LLC; APOLLO ENDOSURGERY, INC.; LPATH THERAPEUTICS INC.
Reel/Frame 058599/0297 →
SECURITY INTEREST Recorded Dec 23, 2021
From: APOLLO ENDOSURGERY, INC.; APOLLO ENDOSURGERY US, INC. (F/K/A LPATH, INC.)
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 058980/0199 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 15, 2019
From: APOLLO ENDOSURGERY, INC.
To: SOLAR CAPITAL LTD., AS COLLATERAL AGENT
Reel/Frame 048885/0621 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 18, 2019
From: ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT
To: APOLLO ENDOSURGERY, INC.
Reel/Frame 048622/0358 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 30, 2016
From: APOLLO ENDOSURGERY, INC.
To: ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT
Reel/Frame 041224/0766 →